Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity.
Wichroski M, Benci J, Liu SQ, Chupak L, Fang J, Cao C, Wang C, Onorato J, Qiu H, Shan Y, Banas D, Powles R, Locke G, Witt A, Stromko C, Qi H, Zheng X, Martin S, Ding M, Gentles R, Meanwell N, Velaparthi U, Olson R, Wee S, Tenney D, Parker CG, Cravatt BF, Lawrence M, Borzilleri R, Lees E. Wichroski M, et al. Among authors: powles r. Sci Transl Med. 2023 Oct 25;15(719):eadh1892. doi: 10.1126/scitranslmed.adh1892. Epub 2023 Oct 25. Sci Transl Med. 2023. PMID: 37878674
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N, Anderson LD Jr, Streetly M, Wilson K, Le HV, Swern AS, Agarwal A, Siegel DS. Jagannath S, et al. Among authors: powles r. Blood Cancer J. 2021 Jun 18;11(6):116. doi: 10.1038/s41408-021-00507-2. Blood Cancer J. 2021. PMID: 34145225 Free PMC article. Clinical Trial.
CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.
Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, Del Genio C, Canfield K, DiRenzo J, Wells W, Gaur A, Robey RB, Guo JY, Powles RL, Sotiriou C, Pusztai L, Febbraio M, Cheng C, Kinlaw WB, Kurokawa M. Feng WW, et al. Among authors: powles rl. Cell Rep. 2019 Dec 10;29(11):3405-3420.e5. doi: 10.1016/j.celrep.2019.11.008. Cell Rep. 2019. PMID: 31825825 Free PMC article.
Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade.
Casadevall D, Li X, Powles RL, Wali VB, Buza N, Pelekanou V, Dhawan A, Foldi J, Szekely B, Lopez-Giraldez F, Hatzis C, Pusztai L. Casadevall D, et al. Among authors: powles rl. JCO Precis Oncol. 2019 May 10;3:PO.18.00335. doi: 10.1200/PO.18.00335. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914041 Free PMC article. No abstract available.
COORDINATION OF MANAGEMENT OF THE ACUTE RADIATION SYNDROME.
Stenke L, Lindberg K, Lagergren Lindberg M, Lewensohn R, Valentin J, Powles R, Dainiak N. Stenke L, et al. Among authors: powles r. Radiat Prot Dosimetry. 2018 Dec 1;182(1):80-84. doi: 10.1093/rpd/ncy144. Radiat Prot Dosimetry. 2018. PMID: 30418654
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C. Powles RL, et al. JAMA Oncol. 2018 Nov 1;4(11):e181564. doi: 10.1001/jamaoncol.2018.1564. Epub 2018 Nov 8. JAMA Oncol. 2018. PMID: 29902299 Free PMC article. Clinical Trial.
407 results